[Hiring] Director, Market Access @Revolution Medicines

Role Description

The Market Access Director, Poland is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.

• Partner with regulatory, commercial and medical affairs teams to deliver launch activities.
• Provide access insights, develop evidence-based HTA, Pricing & Reimbursement dossiers and tools.
• Engage with market access and public affairs stakeholders.
• Drive pricing strategy activities.
• Lead activities to deliver access results supporting overall product launch success aligned with patient needs.

Qualifications

• Advanced degree (e.g., Life Sciences, Pharmacy, Health Economics, Public Health).
• A minimum of 10 years’ experience in market access, pricing, reimbursement or health economics (pharma/biotech) in Poland.
• Proven value and benefit assessment experience, with deep understanding of Poland payer decision-making.
• Demonstrated success and experience supporting oncology product pre-launch, launch and post launch in Poland.
• Demonstrated success in negotiating pricing and reimbursement conditions with public administrations and health authorities.
• Strong stakeholder management and ability to collaborate with internal and external partners.
• Excellent interpersonal and communication skills.
• Scientific and solution-orientated mindset and capability to move and execute in a rapidly changing, ambiguous environment.
• Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments.
• Experience in a biotech and/or in a build-out.
• High capacity of social competence for teamwork, coaching and situational leadership.

Requirements

• Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for RevMed portfolio and launches within the Poland healthcare system.
• HTA & Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments and pricing negotiations with statutory health insurance decision makers.
• Partner with regional and local Medical Affairs and Marketing team to translate clinical and economic evidence into compelling value communications tailored for Poland payers.
• Build and maintain strong relationships with key external stakeholders (payers, HTA authorities, policy influencers).
• Representation of Revolution Medicines at local trade associations for market access subjects.
• Work with Midsized Markets and Regional Market Access teams to align local access strategy with broader European and corporate objectives.
• Provide early market access input to regional and European clinical development and medical teams.
• Lead negotiation with all levels of national payers.
• Develop innovative pricing and value based contracting models to optimize the acceleration of reimbursement approvals.
• Policy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy.
• Represent Market Access in Poland Leadership Team meetings and contribute to overall business strategy.
• Drive access and value related projects such as landscape assessments, payer market research, payer advisory boards and general guidance on local strategies.
• Development of outreach and engagement plan for key payers creating and maintaining a strong network.
• Early access planning of new products and indications, drive launch readiness for multiple oncology assets (portfolio responsibility).
• Influence European and Midsized Markets access strategy based on local payer insights from a leadership position.
• Travel nationally and internationally.

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

• Current RAS(ON) inhibitors in clinical development include:
• daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor;
• elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor;
• zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor;
• RMC-5127, a RAS(ON) G12V-selective inhibitor.